BEDMINSTER, N.J., Nov. 6 /PRNewswire-FirstCall/ --
Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of
needle-free drug delivery systems, will be presenting at The Wall Street
Analyst Forum on Wednesday, November 13, 2002 at 1:20 p.m. EST at the
Roosevelt Hotel in New York City. John Gandolfo, Chief Financial Officer of
Bioject, will be providing a corporate overview and update on recent company
activities. Analysts and portfolio managers who wish to attend the
presentation should contact The Wall Street Analyst Forum at 802-253-7596 to
request additional information.
The presentation will be webcast live by The Wall Street Analyst Forum and
a recording will be made available following the presentation. The webcast
and the recording will be accessible through the Investor Relations section of
Bioject's corporate website at http://www.Bioject.com. To access the live webcast,
please log on to Bioject's site approximately fifteen minutes prior to the
presentation to register and download any necessary audio software.
About Bioject
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with
manufacturing facilities in Portland, Oregon, is an innovative developer and
manufacturer of needle-free drug delivery systems. Needle-free injection
works by forcing medication at high speed through a tiny orifice held against
the skin. This creates a fine stream of high-pressure fluid penetrating the
skin and depositing medication in the tissue beneath. Bioject's partners
include Serono, Alkermes, and Merial.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of the Company,
or industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking
statements. Readers of this press release are referred to the Company's
filings with the Securities and Exchange Commission, including the Company's
reports on Forms 10-K and Forms 10-Q for further discussions of factors that
could affect future results. Forward-looking statements are based on the
estimates and opinions of management on the date the statements are made. The
Company assumes no obligation to update forward-looking statements if
conditions or management's estimates or opinions should change.
For more information on Bioject, visit http://www.bioject.com.
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
Cecelia C. Heer, Investor Relations Manager
of Bioject Medical Technologies Inc., +1-908-470-2800, ext. 5103,
or cheer@bioject.com
|
